Icosavax’s research developing a vaccine for a virus that can lead to deadly respiratory infections in the very young and the very old has found an additional application in the pursuit of a vaccine for the novel coronavirus. The biotech’s $182 million IPO gives it the capital to move forward with clinical research on multiple programs.
RA Capital led the $100 million Series B round of funding for Icosavax, a startup developing vaccines based on virus-like particles. The biotech is preparing for clinical tests of vaccines for respiratory syncytial virus, human metapneumovirus, and SARS-CoV-2.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Digital primary care startup 98point6 is adding digital mental health services to its app. The company added video visits with a therapist or behavioral health coach to its platform.
Ozette applies artificial intelligence to immune monitoring to gain greater insight into a cancer patient's immune system. Beyond informing treatment decisions, the technology can guide drug and diagnostic development.
Nuance Communications acquired Saykara, a startup building a medical AI voice assistant to help with charting and other administrative tasks. The deal is expected to build on Nuance's speech recognition tools for physicians.
Nautilus, among the biotechs developing protein analysis tools for drug discovery and diagnostics, already has a partnership with Genentech. As it prepares to go public, Nautilus aims to do for proteomics what Illumina did for genomics.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Sana Biotechnology is turning new science into novel medicines intended to overcome limitations of current cell therapies. After going from stealth to IPO in two years, it’s now planning to bring multiple programs into clinical testing in 2022.
As hospitals across the country weather a surge of Covid-19 patients, in Seattle — an early epicenter of the outbreak — nurses, respiratory therapists and physicians are staring down a startling resurgence of the coronavirus that’s expected to test even one of the best-prepared hospitals on the pandemic’s front lines.
The startup, which has seen its user base more than triple in the last year, plans to use the funds to further build out its platform.
The company has received FDA approvals for two cancer drugs in less than 12 months and announced partnerships with Merck last month for a Phase II antibody-drug conjugate and a marketed drug.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Seattle-based optimize.health raised $15.6 million in a series A round. The company developed a software platform to support remote patient monitoring.
The co-founders of the company include Hans Bishop, who founded Juno Therapeutics - one of the earliest commercial developers of CAR-T cell therapy technology - in 2013.
The Seattle-based company is one of several that have raised venture capital and equity investment funding this week.
98point6, a startup offering text-based primary care services, said it added Boeing, Chipotle, Circle K and other large companies as customers.
In the midst of the Covid-19 pandemic, two emergency physicians in Seattle and Sacramento shared what cases they’re seeing and what strategies they’re using to prepare for the virus.